[PEGS 2022] Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
- Version:
- 21238
- File Name/Number:
- PEGS
- Year:
- 2022
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have proved to be powerful agents to restore anti-tumor immune responses.